Transgenic mice bearing a human mutant thyroid hormone β1 receptor manifest thyroid function anomalies, weight reduction, and hyperactivity

Molecular Medicine

Volumn 3, Issue 5, 1997, Pages 303-314

  Wong, Rosemary ^a   Vasilyev, Vyacheslav V ^a   Ting, Yuan Tsang ^b   Kutler, David I ^a   Willingham, Mark C ^c   Weintraub, Bruce D ^a   Cheng, Sheue Yann ^b,d  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d Building 37 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; THYROID HORMONE RECEPTOR; THYROTROPIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; FEMALE; HYPERACTIVITY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ANALYSIS; THYROID DISEASE; THYROID FUNCTION TEST; THYROID HORMONE RESISTANCE; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; WEIGHT REDUCTION;

EID: 0030849020     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03401809     Document Type: Article

References (34)

1. Cheng S-y (1995) New insights into the structure and function of the thyroid hormone receptor. J. Biomed. Sci. 2: 77-89.
2. Oppenheimer JH, Schwanz HL, Strait KA (1994) Thyroid hormone action 1994: The plot thickens. Eur. J. Endocrinol. 130: 15-24.
3. Yap N, Yu C-L, Cheng S-y (1996) Modulation of the transcriptional activity of thyroid hormone receptors by the tumor suppressor p53. Proc. Natl. Acad. Sci. U.S.A. 93: 4273-4277.
4. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L (1996) Nuclear receptor coactivators and corepressors. Mol. Endocrinol. 10: 1167-1177.
5. Refetoff S, Weiss RE, Usala SJ (1993) The syndromes of resistance to thyroid hormone. Endocr. Rev. 14: 348-399.
6. Usala SJ (1995) New developments in clinical and genetic aspects of thyroid hormone resistance syndromes. The Endocrinologist 5: 68-76.
7. Refetoff S, DeWind LT, DeGroot LJ (1967) Familial syndrome combining deaf mutism, stippled epiphyses, goiter, and abnormally high PBI: Possible target organ refractoriness to thyroid hormone. J. Clin. Endocrinol. Metab. 27: 279-294.
8. Brucker-Davis F, Skarulis MC, Grace MB, Benichou J, Hauser P, Wiggs E, Weintraub BD (1995) Genetic and clinical features of 42 kindreds with resistance to thyroid hormone: The NIH prospective study. Ann. Intern. Med. 123: 572-583.
9. Yen PM, Chin WW (1994) Molecular mechanisms of dominant negative activity by nuclear hormone receptors. Mol. Endocrinol. 8: 1450-1454.
10. Hayashi Y, Mangoura D, Refetoff S (1996) A mouse model of resistance to thyroid hormone produced by somatic gene transfer of a mutant thyroid hormone receptor. Mol. Endocrinol. 10: 100-106.
11. Barlow C, Meister B, Lardelli M, Lendahl U, Vennstrom B (1994) Thyroid abnormalities and hepatocellular carcinoma in mice transgenic for v-erbA. EMBO J. 13: 4241-4250.
12. Sap J, Munoz A, Damm K, Goldberg Y, Ghysdael J, Leutz A, Beug H, Vennstrom B (1986) The c-erbA protein is a high affinity receptor for thyroid hormone. Nature 324: 635-640.
13. Weinberger C, Thompson CC, Ong ES, Lebo R, Gruol DJ, Evans RM (1986) The c-erbA gene encodes a thyroid hormone receptor. Nature 324: 641-646.
14. Forrest D, Hanebuth E, Smeyne RJ, Everds N, Stewart CL, Wehner JM, Curran T (1996) Recessive inheritance to thyroid hormone in mice lacking thyroid hormone receptor β: Evidence for tissue-specific modulation of receptor function. EMBO J. 15: 3006-3015.
15. Takeda K, Sakurai A, DeGroot LJ, Refetoff S (1992) Recessive inheritance of thyroid hormone resistance caused by complete deletion of the protein-coding region of the thyroid hormone receptor-β gene. J. Clin. Endocrinol. Metab. 74: 49-55.
16. W42 minigene in transgenic mice: Recapitulation of W phenotypes and evidence for c-kit function in melanoblast progenitors. Genes Dev. 5: 2265-2273.
17. Gunning P, Leavitt J, Muscat G, Ng S-Y, Kedes L (1987) A human beta-actin expression vector system directs high-level accumulation of antisense transcripts. Proc. Natl. Acad. Sci. U.S.A. 84: 4831-4835.
18. Parrilla RA, Mixson AJ, McPherson JA, McClaskey JH, Weintraub BD (1991) Characterization of seven novel mutations of the c-erbAβ gene in unrelated kindreds with generalized thyroid hormone resistance. Evidence for two "hot spot" regions of the ligand binding domain. J. Clin. Invest. 88: 2123-2130.
19. Meier CA, Dickstein BM, Ashizawa K, McClaskey JH, Muchmore P, Ransom SC, Menke JB, Hao E-H, Usala SJ, Bereu BB, Cheng S-y, Weintraub BD (1992) Variable transcriptional activity and ligand binding of mutant beta-1 3,5,3′-triiodothyronine receptors from four families with generalized resistance to thyroid hormone. Mol. Endocrinol. 6: 248-258.
20. Hogan B, Lacy E (1986) Manipulating the Mouse Embryo. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
21. Bhat MK, McPhie P, Ting Y-T, Zhu X-G, Cheng S-y (1995) Structure of the carboxy-terminal region of thyroid hormone nuclear receptor and its possible role in hormone-dependent intermolecular interactions. Biochemistry 34: 10591-10599.
22. Hasumura S, Kitagawa S, Lovelace E, Willingham MC, Pastan I, Cheng S-y (1986) Characterization of a membrane-associated 3,3′,5-triiodo-L-thyronine binding protein by use of monoclonal antibodies. Biochemistry 25: 7881-7888.
23. Fitzgerald RE, Berres M, Schaeppi U (1988) Validation of a photobeam system for assessment of motor activity in rats. Toxicology 49: 433-439.
24. Zametkin AJ, Rapoport JL (1987) Neurobiology of attention-deficit disorder with hyperactivity: Where have we come in 50 years? J. Am. Acad. Child. Adolesc. Psychiatry 26: 676-686 [Erratum, (1988) 27: 338].
25. Hauser P, Zametkin AJ, Martinez B, Vitiello B, Matochik JA, Mixson AJ, Weintraub BD (1993) Attention defidt-hyperactivity disorder in people with generalized resistance to thyroid hormone. N. Engl. J. Med. 328: 997-1001.
26. Shenker A (1992) The mechanism of action of drugs used to treat attention-deficit hyperactivity disorder: Focus on catecholamine receptor pharmacology. Adv. Pediatr. 39: 337-382.
27. Malone MA, Kershner JR, Swanson JM (1994) Hemispheric processing and methylphenidate effects in attention-deficit hyperactivity disorder. J. Child Neurol. 9: 181-189.
28. Shaywitz BA, Teicher MH, Cohen DJ, Anderson GM, Young JG, Levitt P (1984) Dopaminergic but not adrenergic mediation of hyperactivity and performance deficits in the developing rat pup. Psychopharmacology 82: 73-77.
29. Xu M, Hu X-T, Cooper DC, Moratalla R, Graybiel AM, White FJ, Tonegawa S (1994) Elimination of cocaine-induced hyperactivity and dopamine-mediated neurophysiological effects in dopamine D1 receptor mutant mice. Cell 79: 945-955.
30. Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park B-H, Gauda EB, Lee EJ, Cool MH, Sihley DR, Gerfen CR, Westphal H, Fuchs S (1996) A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc. Natl. Acad. Sci. U.S.A. 93: 1945-1949.
31. Archer T, Danysz W, Fredriksson A, Jonsson G, Luthman J, Sundstrom E, Teiling A (1988) Neonatal 6-hydroxydopamine-induced dopamine depletions: Motor activity and performance in maze learning. Pharmacol. Biochem. Behav. 31: 357-364.
32. Power RF, Mani SK, Codina J, Conneely OM, O'Malley BW (1991) Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 254: 1636-1639.
33. Crocker AD, Overstreet DH (1984) Modification of the behavioral effects of haloperidol and of dopamine receptor regulation by altered thyroid status. Psychopharmacology 82: 102-106.
34. Strait KA, Schwanz HL, Perez-Castillo A, Oppenheimer JH (1990) Relationship of c-erbA mRNA content to tissue triiodothyronine nuclear binding capacity and function in developing and adult rats. J. Biol. Chem. 265: 10514-10521.